Serum fatty acid binding protein 5 (FABP5) as a potential biomarker of inflammation in psoriasis

Abstract

Fatty acid binding protein 5 (FABP5) is elevated in psoriatic keratinocytes and could be involved in systemic metabolic disturbances in psoriasis. The aim of the study was to evaluate serum FABP5 in obese and non-obese psoriatic patients, to assess the relationship between FABP5 and the duration, severity of the disease, inflammatory and metabolic markers and influence of treatment with narrowband—ultraviolet B (NB-UVB). Seventy-four patients (30 treated with NB-UVB) with psoriasis were enrolled in the study. The serum concentrations of FABP5 were measured using Human FABP5 Enzyme-Linked Immunosorbent Assay kit. Serum fatty acids were measured by gas–liquid chromatography. Serum FABP5 levels in psoriatic patients were higher versus control group (P\u2009<\u20090.001). FABP5 in patients with PASI\u2009>\u200920 was higher compared to the mild group (PASI\u2009<\u200910) (P\u2009<\u20090.001) and serum FABP5 correlated positively with PASI score (r\u2009=\u20090.41, P\u2009<\u20090.001). There was also positive correlation between FABP5 and basic inflammation indices. Decrease of PASI after NB-UVB treatment (P\u2009<\u20090.001) was observed and accompanied by decrease of the serum FABP5 (P\u2009=\u20090.007). FABP5 is a potential marker of psoriasis, its severity and clinical outcome after therapy with NB-UVB. FABP5 may reflect metabolic disturbances in psoriatic patients.